Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift

September 5, 2023

Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the clinic. The majority of these candidates aim at undruggable cancer targets usually involved in signal transduction, transcription regulation, scaffolding, etc.

These targets also present challenges in the biophysical characterization of the binary and ternary complex interactions, making developing effective degraders much more complicated — and potentially leaving your company lagging behind your competitors.

Watch this on-demand webinar to learn how Dianthus — a plate-based affinity screening platform with breakthrough Spectral Shift technology — overcomes the challenges for the biophysical characterization of binary and ternary complexes of 5 PROTACs against cancer target WD-Repeat-Containing Protein 5 (WDR5).

No Previous Videos

Up next
How to keep your degrader pipeline moving forward with Dianthus
How to keep your degrader pipeline moving forward with Dianthus

The development of your protein degrader is a multi-step and complex process usually packed with challenges...

Want to see more
PROTACs content?

Explore resources